<DOC>
	<DOCNO>NCT02630121</DOCNO>
	<brief_summary>The addition intranasal oxymetazoline two week already institute optimal dos intranasal fluticasone propionate decrease total number obstructive apnea hypopneas per hour sleep subject perennial allergic non-allergic rhinitis mild obstructive sleep apnea persistent nasal congestion despite maximum dos NGCS .</brief_summary>
	<brief_title>Effect Oxymetazoline Hydrochloride Comibination With Fluticasone Propionate Apnea Hypopnea Index ( AHI ) Subject With Persistent Nasal Congestion Mild Obstructive Sleep Apnea</brief_title>
	<detailed_description>To evaluate effectiveness addition intranasal oxymetazoline ongoing optimal dos intranasal fluticasone propionate apnea/hypopnea index ( AHI ) subject persistent nasal congestion mild obstructive sleep apnea secondary perennial allergic non-allergic rhinitis despite treatment recommend dos NGCS . The NOX T3 portable sleep monitor use measure AHI . 1 . The Flow Sensor , part NOX T3 portable monitor , use assess flow limitation upper airway calculation flatten index , marker upper airway resistance . 2 . The Congestion Quantifier 7 ( CQ7 ) questionnaire use assess improvement nasal congestion base symptom prior week . 3 . The Nasal Congestion Visual Analog Scale ( VAS ) use identify change severity nasal congestion day day basis . 4 . The Rhinoconjunctivitis Quality Life Questionnaire ( RQLQ ) use assess impact perennial rhinitis nasal congestion activity daily live .</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<criteria>1 . Male female subject 18 65 year age . 2 . At least one year history perennial allergic nonallergic rhinitis . 3 . Subjects must maximum recommended dos one follow NGCS least one month . ( See Table I ) 4 . AHI per hour sleep &gt; 5 &lt; 15 , minimum SpO2 88 , indicate mild obstructive sleep apnea ) . 5 . Average Nasal Congestion VAS &gt; 310 indicate moderate severe nasal congestion visit 1 2 base daily symptom ( average 7 score ) . 6 . Average Congestion Quantifier 7 score 7 visit 1 2 base weekly symptom ( average 2 score ) . 7 . Willingness participate indicate sign informed consent . 1 . Presence hypersensitivity oxymetazoline fluticasone propionate . 2 . Subjects receive allergen immunotherapy stable maintenance regimen least 30 day first study visit . 3 . If subject perennial allergic rhinitis , he/she enter study eight week , , six week seasonal exacerbation . 4 . Women pregnant lactating . 5 . Other know nasal diseases likely affect deposition oxymetazoline sinusitis , nasal polyp , major nasal structural malformation . 6 . Respiratory tract infection last 14 day . 7 . Infections require antibiotic last 14 day . 8 . Asthma chronic obstructive pulmonary disease ( COPD ) require roflumilast recommend dos inhaled corticosteroid , beta agonist , antimuscarinic agent . 9 . No systemic glucocorticosteroids one month prior study . 10 . Cardiovascular disease uncontrolled hypertension ( BP160/80 ) , arrhythmias and/or congestive heart failure . 11 . Insulindependent diabetes mellitus and/or diabetic retinopathy . 12 . Subjects mild OSA ( AHI 514 ) SpO2 &lt; 88 &gt; 5 min sleep identify screen portable sleep study . 13 . Hypertension require two drug , exception hydrochlorothiazide , achieve control . 14 . A history drug alcohol abuse within past 5 year . 15 . Subjects currently abuse alcohol , illicit drug , benzodiazepine , narcotic . 16 . Inability cooperate , comply study procedure communicate investigator successfully complete study . 17 . A history benign prostate hypertrophy necessitate treatment . 18 . A history psychiatric problem , opinion investigator , would impair participation study . 19 . Subjects plan hospitalization study . 20 . An infirmity , disability , geographical location seem likely prevent regular attendance subject visit . 21 . Subjects obstructive sleep apnea syndrome require CPAP therapy . 22 . Subjects diagnosed central sleep apnea ( &gt; 5 central event per hour ) moderate severe OSA ( AHI &gt; 15 ) SpO2 &lt; 88 &gt; 5 min sleep identify screen . 23 . Use following medication within time period specify prior Day 7 ( Table 2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>